Cardio Diagnostics
Develops epigenetic and genetic blood tests to assess coronary heart disease risk.
What they do
Develops integrated genetic epigenetic clinical blood tests to detect and assess the risk of coronary heart disease. The tests are ordered by primary care clinics and cardiologists to identify patients at risk before clinical events manifest.
The record
- Vertical
- Cardiovascular
- Sub-segment
- Epigenetic cardiac diagnostics
- Product type
- Diagnostics
- Stage
- Public
- Headquarters
- Chicago, United States
- Region
- North America
- Founded
- 2017
- Total funding
- $15M raised
Notable investors: University of Iowa, Angels.